Biomedical Occupation or Discipline
Lilly Opens State-of-the-Art Research and Development Center in Boston
Lilly, Boston, research and development, genetics research, biotech incubator, East Coast hub
23andMe Shifts Focus to GLP-1 Telehealth Offering, Cuts Internal Drug Development Team
23andMe, GLP-1, telehealth, weight loss, drug development, layoffs
Exelixis Abandons Tissue Factor-Targeting ADC Due to Competition from Tivdak
Exelixis, tissue factor-targeting ADC, Tivdak, biotech, pharmaceuticals, drug development
Sangamo Partners with Genentech for $1.9 Billion Neurology-Focused Deal Using Zinc Finger Technology
Sangamo, Genentech, zinc finger technology, neurology, Alzheimer’s disease, tau gene, biobucks, biopharma, gene therapy, Fabry disease
Mallinckrodt to Sell Therakos Business Unit to CVC Capital for $925 Million
Mallinckrodt, Therakos, CVC Capital Partners, photopheresis, extracorporeal photopheresis, ECP, cutaneous T-cell lymphoma, CTCL, immunotherapy, pharmaceuticals, medical technology, healthcare services
Ultimovacs Cancer Vaccine Faces Significant Challenges After Third Consecutive Failure
Ultimovacs, cancer vaccine, phase 2 trial, clinical failure, financial struggles, biotechnology
GSK Partners with Flagship Pioneering in $7 Billion Biobucks Deal for Respiratory and Immunology Research
GSK, Flagship Pioneering, biobucks, respiratory research, immunology research, pharmaceutical partnership
Roche Accelerates Obesity Drug Development and Explores M&A Opportunities
Roche, obesity drugs, M&A, pharmaceuticals, drug development
Biogen Retains Biosimilars as Eisai-Partnered Leqembi Advances Amid Business Shift
Biogen, biosimilars, Leqembi, Eisai, Alzheimer’s disease, business pivot, pharmaceuticals, biotechnology
Pinetree Therapeutics Secures $17M in Funding to Advance Targeted Protein Degraders
Pinetree Therapeutics, targeted protein degraders, TPD, Series A funding, pharmaceutical development